NEW YORK (GenomeWeb News) - Geron licensed its intellectual property related to the growth of human embryonic stem cells to Invitrogen, Invitrogen said today.
Under the non-exclusive license agreement, Invitrogen can use Geron's patents to develop, manufacture, and sell media, additives, and reagents for use by hESC researchers. Some commercial use restrictions apply.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.